Navigation Links
Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Date:10/20/2009

> Dr. Colin Goddard, Chief Executive Officer of OSI Pharmaceuticals added, "As a leading Chinese pharmaceutical company with a successful track record of developing and commercializing oncology products in China, we are confident that Simcere has the right capabilities and resources to successfully manufacture, develop and market OSI-930 in China. We are looking forward to working with Simcere on this exciting collaboration."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "pr
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the global leader ... announced that Robert A. Ingram has retired from ... ardent champion for innovation in the lifesciences industry, and it ... board as we pursue our focused innovation strategy," said ... provided a valuable perspective to our board, drawing on his ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Results from Gene Identification Studies Presented at ASCO Support, ... ... REDWOOD CITY, Calif., May 31 Genomic Health,Inc. (Nasdaq: GHDX ... of two separate studies presented at the annual,meeting of the American ...
... from Phase III clinical trial --, CHICAGO, ... today announced the presentation of updated results from,a ... comparing,VELCADE and dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone ... of,19 percent in the VcD arm as induction ...
Cached Medicine Technology:Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 2Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 3Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 4Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, ... Inc. has re-branded their social media profiles to better connect with the public. ... to communicate, find information, share insights and opinions. The Rally Insurance Group, Inc.’s ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... Ticket ... Theatre . Those looking to catch a new and refreshing show on Broadway, ... numerous awards and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... ranging from crushing depression and crippling anxiety to powerful delusions ... real from the imagined. And if that weren,t enough, ... of the world perceives their inner struggle. Stigma ...
... , THURSDAY, Dec. 29 (HealthDay News) -- Individuals may ... if they carry abnormalities in the so-called "ATM" gene, ... upcoming issue of Cancer Discovery , stems from ... comparative purposes, 190 other individuals who did not have ...
... Dec. 29, 2011--Dr. Andrew Advani, an endocrinologist at St. ... America who received a newly created Novo Nordisk Diabetes ... worth $325,000 (U.S.) over two years. His research ... in patients suffering from diabetes. In diabetic kidney disease, ...
... HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay News) ... and vitamins B, C, D and E in their blood ... tended to have larger brain volume, a new study finds. ... blood fared worse on certain thinking tests than those with ...
... Disease-causing strains of the fungus Fusarium are present ... of infection in humans, according to a new study. ... agricultural crops, but some species of the fungus can cause ... example, Fusarium was the cause of an outbreak ...
... crystal-clear tunes at high volume for hours on end ... according to Tel Aviv University research, these advances have also ... teenagers as the most at-risk group. One ... as a direct result of these listening habits, says Prof. ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:Gene Mutation May Be Key to Familial Pancreatic Cancer 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 3Health News:Fungus Found in Sinks Can Cause Serious Infections 2Health News:Turn down the iPod to save your hearing 2
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Regular tip. 1 mm x 13 mm. Serrated. Insulated....
Colibri style with 1.5 mm long angled tip and 0.12 mm teeth. Serrated handles with polished finish....
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws straight....
Medicine Products: